瑞桥鼎科集团与Cosmotec达成里程碑式战略合作
公司动态
2025.09.15
111
Forge Landmark Partnership
瑞桥鼎科集团与Cosmotec
达成里程碑式战略合作
2025年9月15日
2025年9月15日，瑞桥鼎科集团宣布与Cosmotec株式会社（M3全资子公司，东证代码：2413）就日本市场达成独家商业化合作。
SHANGHAI,Sept.15,2025 -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market.
此次战略合作充分体现了瑞桥鼎科集团在自主研发、合规管理以及价值驱动生态协作方面的领导优势，标志着公司全球化战略迈出重要步伐，进一步提升国际市场影响力。同时，该合作也突显了Cosmotec顶尖数字化商业平台的优势，该平台能加速国际医疗器械的市场准入，实现与临床终端用户的精准对接。
This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence.Simultaneously, the partnership underscores Cosmotec's best-in-class digital commercialization platform, which accelerates market access for international medical devices and enables targeted engagement with clinical end-users.
左：王俭 Jay Wang
右：大凑卓 Suguru Ominato
Cosmotec首席执行官 大凑卓
Suguru Ominato，CEO of Cosmotec
瑞桥鼎科集团旗下产品组合在临床效能和人性化设计方面表现卓越，完美契合日本医生对先进治疗方案的追求。通过将M3学术平台与我们本土化的商业专长相结合，必将加速这些器械在全日本市场的推广应用。
EverBridge Group's portfolio demonstrates outstanding clinical efficiency and user-friendly design, aligning perfectly with Japanese physicians' pursuit of advanced therapeutic solutions," stated Suguru Ominato, CEO of Cosmotec. "By integrating M3's academic platforms with our localized commercialization expertise, we will accelerate the adoption of these devices across the Japanese market.
瑞桥鼎科集团首席执行官 王俭
Jay Wang，CEO of EverBridge Group
Cosmotec的数字化商业模式兼具高效性与可及性，这与我们推动公平医疗创新的愿景高度契合。此次合作不仅使我们能顺利应对日本严格的技术监管环境，为患者带来变革性解决方案，更深化了全球研发协同。通过创新与生态协作降低先进医疗门槛，始终是我们全球化进程的核心使命。
Cosmotec's digital commercialization model delivers both efficiency and accessibility, which aligns perfectly with our vision for equitable healthcare innovation," said Jay Wang, CEO of EverBridge Group. "By navigating Japan's rigorous technical and regulatory landscape, this partnership not only delivers transformative solutions to patients but also enhances our global R&D synergy. Lowering barriers to advanced care through innovation and ecosystem collaboration remains central to our globalization journey.
伴随“健康中国2030”战略的深入推进及全球医疗需求的持续增长，瑞桥鼎科集团“引进来、走出去”出海战略持续深度实践，是中国医疗器械企业实现“产品出海”向“价值出海”的跨越。瑞桥鼎科集团会坚持以坚实的技术创新为根基，以合规精益运营与品牌建设为双翼，并通过构建生态合作突破资源限制，为全球医疗创新贡献重要的力量。
Driven by the "Healthy China 2030" strategy and the growing global medical demands, EverBridge Group is deeply implementing its "Bring in, Go Global" strategy, pioneering the transition from “product export” to “value export” among Chinese medical device enterprises.
EverBridge Group will continue to build on a solid foundation of technological innovation, powered by the two engines of compliant lean operations and brand building, and break through resource constraints by fostering ecological collaborations, thereby contributing significantly to global medical innovation.
【END】
